27 febrero 2015
About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a new study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/W7xI2RANVCg/150227181341.htm
